Migraine drug not cost effective NICE says in final draft guidance
NICE has said that a new drug for preventing migraine is not a cost effective use of NHS resources.
Its draft guidance looks at erenumab (also called Aimovig and made by Novartis) for preventing chronic and episodic migraine in adults who have four episodes or more of migraine every month and where at least three other preventive treatments haven’t worked.
